Christiane Langer

7.5k total citations · 4 hit papers
26 papers, 5.8k citations indexed

About

Christiane Langer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Christiane Langer has authored 26 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Christiane Langer's work include Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Christiane Langer is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Christiane Langer collaborates with scholars based in United States, Canada and Australia. Christiane Langer's co-authors include Christos S. Karapetis, Derek J. Jonker, Dongsheng Tu, Niall C. Tebbutt, Malcolm J. Moore, John Zalcberg, Timothy Price, R. J. Simes, Chris J. O’Callaghan and Shirin Khambata‐Ford and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Christiane Langer

26 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 2.8k citations Christos S. Karapetis, Shirin Khambata‐Ford et al. New England Journal of Medicine profile →
Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. New England Journal of Medicine profile →
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

2008 726 citations Heinz‐Josef Lenz, Christiane Langer et al. Journal of Clinical Oncology profile →
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

2015 340 citations Fotios Loupakis, Dongyun Yang et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Christiane Langer

Since Specialization

Citations

This map shows the geographic impact of Christiane Langer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christiane Langer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christiane Langer more than expected).

Fields of papers citing papers by Christiane Langer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christiane Langer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christiane Langer. The network helps show where Christiane Langer may publish in the future.

Co-authorship network of co-authors of Christiane Langer

This figure shows the co-authorship network connecting the top 25 collaborators of Christiane Langer. A scholar is included among the top collaborators of Christiane Langer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christiane Langer. Christiane Langer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer breakdown → 2015 ·JNCI Journal of the National Cancer Institute ·Fotios Loupakis, Dongyun Yang, Linda Yau, Shibao Feng, Chiara Cremolini, Wu Zhang, Martin Maus, Carlotta Antoniotti, Christiane Langer, Stefan Scherer, Thomas Müller, Herbert I. Hurwitz, Leonard B. Saltz, Alfredo Falcone, Heinz‐Josef Lenz	340
2	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer 2013 ·British Journal of Cancer ·Derek J. Jonker, Christos S. Karapetis, Christopher Harbison, Christopher J. O’Callaghan, Dongsheng Tu, R. J. Simes, Daniel P. Malone, Christiane Langer, Niall C. Tebbutt, Timothy Price, Joël Shapiro, Lillian L. Siu, (unknown), Georg A. Bjarnason, Malcolm J. Moore, John Zalcberg, Shirin Khambata‐Ford	64
3	MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC). 2012 ·Journal of Clinical Oncology ·Sachdev Thomas, Suprith Badarinath, Richard H. Greenberg, (unknown), (unknown), Shibao Feng, Stefan Scherer, (unknown), Christiane Langer, Heinz‐Josef Lenz	5
4	Human epidermal growth factor receptor-2 (HER2) Ile655Val single nucleotide polymorphism (SNP) is associated with gender-specific outcome in patients with metastatic colorectal cancer (mCRC) treated with cetuximab in a phase II study (IMCL-0144). 2011 ·Journal of Clinical Oncology ·Armin Gerger, Pierre Bohanes, Dawei Yang, Thomas Winder, Yan Ning, Melissa J. LaBonte, David J. Mauro, Christiane Langer, Eric K. Rowinsky, H.J. Lenz	3
5	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients 2010 ·Clinical Cancer Research ·Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	43
6	A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy 2010 ·Annals of Oncology ·(unknown), Thomas Winder, Yan Ning, (unknown), Dongyun Yang, Michael Kahn, Georg Lurje, Melissa J. LaBonte, P. M. Wilson, Michael A. Gordon, Siwen Hu‐Lieskovan, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	107
7	Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care 2010 ·Annals of Oncology ·(unknown), Erin Powell, Christos S. Karapetis, Derek J. Jonker, Dongsheng Tu, Mark Jeffery, Nick Pavlakis, Peter Gibbs, (unknown), (unknown), Renaud Whittom, Christiane Langer, Chris J. O’Callaghan	33
8	Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871) 2009 ·Journal of Clinical Oncology ·Mary L. Hixon, Antonio Gualberto, Laurence M. Demers, Luis Paz‐Ares, Silvia Novello, L. Johnetta Blakely, Christiane Langer, Allan Lipton, Michaël Pollak, Daniel D. Karp	8
9	Association of a germ-line variant in the K-ras 3’ untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status 2009 ·Journal of Clinical Oncology ·Thomas Winder, W. Zhang, Anthony B. El-Khoueiry, Daniel X. Yang, (unknown), Georg Lurje, Eric K. Rowinsky, Shirin Khambata‐Ford, Christiane Langer, (unknown), Heinz‐Josef Lenz	5
10	Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium 2009 ·Journal of Clinical Oncology ·Tanya Trippett, Cynthia E. Herzog, James A. Whitlock, Johannes Wolff, John F. Kuttesch, Rochelle Bagatell, Stephen P. Hunger, Jessica Boklan, Amy Smith, R.J. Arceci, Howard M. Katzenstein, Christopher Harbison, Xiaofei Zhou, Haolan Lu, Christiane Langer, Martin R. Weber, Lia Gore	38
11	K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer breakdown → 2008 ·New England Journal of Medicine ·Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, Chris J. O’Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. J. Simes, Haji Chalchal, Jeremy Shapiro, (unknown), Timothy Price, Lois E. Shepherd, Heather‐Jane Au, Christiane Langer, Malcolm J. Moore, John Zalcberg	2764
12	Polymorphisms inCyclooxygenase-2andEpidermal Growth Factor ReceptorAre Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab 2008 ·Clinical Cancer Research ·Georg Lurje, Fumio Nagashima, Wu Zhang, Dongyun Yang, Heung Moon Chang, Michael A. Gordon, Anthony B. El-Khoueiry, Hatim Husain, Peter M. Wilson, Robert D. Ladner, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	93
13	Cetuximab for the Treatment of Colorectal Cancer breakdown → 2007 ·New England Journal of Medicine ·Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis, John Zalcberg, Dongsheng Tu, (unknown), Scott Berry, Marianne Krahn, Timothy Price, R. J. Simes, Niall C. Tebbutt, Guy van Hazel, (unknown), Christiane Langer, Malcolm J. Moore	1413
14	A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors 2007 ·Journal of Clinical Oncology ·Tanya Trippett, John F. Kuttesch, Charles A. Herzog, Jessica Boklan, Rochelle Bagatell, Stephen P. Hunger, R.J. Arceci, Haolan Lu, Christiane Langer, Lia Gore	1
15	Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer 2006 ·Cancer Research ·(unknown), (unknown), Xin Huang, Tai W. Wong, Suso Platero, Christiane Langer, (unknown), Lynn Ploughman, Edwin Clark, David J. Mauro	3
16	Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials 2006 ·Journal of Clinical Oncology ·(unknown), P. Bonomi, Christiane Langer, Kenneth J. O’Byrne, B. Bandstra, Helen J. Ross, Alan N. Sandler, Mark A. Socinski, Luis Paz‐Ares	5
17	Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial 2005 ·Journal of Clinical Oncology ·Jonathan Polikoff, Edith P. Mitchell, (unknown), (unknown), (unknown), (unknown), Tarah Gustafson, Christiane Langer	39
18	P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial 2005 ·Lung Cancer ·Pasi A. Jänne, George R. Simon, Christiane Langer, Taub Rn, Afshin Dowlati, P. Fidias, L. P. Bloss, (unknown), Coleman K. Obasaju, Hedy L. Kindler	1
19	Reactive Oxygen Species Act at both TGF-β-Dependent and -Independent Steps during Induction of Apoptosis of Transformed Cells by Normal Cells 1996 ·Experimental Cell Research ·Christiane Langer, Juliane M. Jürgensmeier, (unknown)	57
20	Prostanoids Inhibit Release of Endogenous Norepinephrine from Rat Isolated Trachea 1992 ·American Review of Respiratory Disease ·Kurt Racké, (unknown), Christiane Langer, Matthias Bräutigam, Ignaz Wessler	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact